NEW YORK, April 2, 2020 /PRNewswire/ --The Muscular Dystrophy Association (MDA) announced today the formation of its formal Medical Advisory Team who provide MDA with strategic guidance on issues that impact research and clinical care for people living with muscular dystrophy, amyotrophic lateral sclerosis (ALS) and related neuromuscular disorders more than 43 diseases. Each of the team members is a leading clinician at an MDA Care Center and is an internationally known expert in muscular dystrophy, ALS and related neuromuscular diseases. The MDA Care Center network spans over 150 locations at the nation's top medical institutions.
"We believe that engaging this team of world-class experts across neuromuscular diseases will enable MDA to lead the way in speeding the development of groundbreaking therapies and treatment paradigms that will transform the lives of those we serve," says Lynn O'Connor Vos, President and CEO of MDA. "These physicians are pillars of the neuromuscular disease community, each with focused expertise in specific diseases. Together, they will provide critical advice to MDA on our innovations in science and care programs and help ensure that we are making the maximum impact as the landscape of neuromuscular research, care and treatments evolve."
MDA's medical advisors will help lead the effort, along with more than 2,000 health care providers, to establish new clinical trials geared toward integration of MDA's innovative MOVR technology hub, which allows clinicians and researchers to share a wealth of disease-related information, establish professional protocols, and accelerate innovation.
Tonight, Dr. Barry Byrne, who will serve as chief medical advisor for the team, is joining MDA's EVP, Chief Advocacy & Care Services Officer, Kristin Stephenson for an MDA Facebook Live conversation about the precautions and best practices needed to protect the neuromuscular community in light of COVID-19. The event, scheduled for Thursday, April 2 from 6:00 to 6:30 pm EDT is accessible at https://www.facebook.com/MDAOrg/. The recording will be available for viewing after the event on MDA's COVID-19 resource page. The conversation will feature a live Q&A answering questions from people living with muscular dystrophy, ALS and related neuromuscular diseases including MDA families, and aims to provide the answers to questions regarding care duringthese uncertain times, and will cover topics related to preparedness, community impact, telemedicine and MDA's Care Center network of over 150 multidisciplinary care teams at top medical institutions nationwide.
Barry J. Byrne, MD, PhD, is an ardent supporter of newborn screening and has been an innovator and early adopter of new FDA-approved therapies that have the potential to alter the course of some neuromuscular disorders. He was the first physician to administer an approved gene therapy to a neuromuscular patient in the U.S.
"We are just beginning to realize the impact of the current revolution in the treatment of neuromuscular disorders. Newborn screening and access to newly-approved therapies are changing patients' lives when diagnosed with neuromuscular diseases; the MDA Care Center network is ready to provide these innovative treatments," says Dr. Byrne. "Disease-modifying therapies are no longer a thing of the future. There is an urgent need to bring innovative care, cutting-edge clinical research and new breakthrough treatments to the community."
Dr. Byrne will continue in his role as the associate chair of pediatrics and director of the Powell Gene Therapy Center at the University of Florida College of Medicine as he assumes this new position. He is also director of the MDA Care Center at the University of Florida.
Matthew B Harms, MD, will serve as a medical expert on ALS and other neuromuscular disorders. He is active in clinical research. Dr. Harms is associate professor of neurology at Columbia University's Vagelos College of Physicians and Surgeonsand serves at MDA's ALS Care Center at Columbia University. Dr. Harms received MDA's Diamond Award for his work directing an international effort with whole genome and transcriptome sequencing to bring precision medicine to ALS treatments.
John W. Day, MD, PhD, completes the Medical Advisory Team. Dr. Day is professor of neurology and pediatrics and director, Division of Neuromuscular Medicine at Stanford University. He directs Stanford's MDA Care Centers, which uniquely integrate the Lucile Packard Children's Hospital Pediatric and Transitional Neuromuscular Clinic with the Stanford Hospital Neuroscience Health Center's Neuromuscular and ALS Research and Clinic.The comprehensive team of investigators and clinicians in the Stanford Neuromuscular Program have helped develop novel gene modification and gene replacement treatments for spinal muscular atrophy, muscular dystrophy and ALS, and have spearheaded development of centralized data hubs like MDA's MOVR for neuromuscular disease.
About Barry J. Byrne, MD, PhD
Dr. Byrne is a clinician scientist who is studying a variety of rare diseases with the specific goal of developing therapies for inherited muscle disease. As a pediatric cardiologist, his focus is on conditions that lead to skeletal muscle weakness and abnormalities in heart and respiratory function. His group has made significant contributions to the understanding and treatment of Pompe disease, a type of neuromuscular disorder caused by an excess of a type of sugar (glycogen) in certain muscles. The research team has pioneered the use of adeno-associated virus (AAV) mediated gene therapy to restore heart and skeletal muscle function in Duchenne muscular dystrophy, Pompe, Friedrich's ataxia and other neuromuscular diseases. His group at the Powell Center has also established a series of new methods for large-scale AAV manufacturing to enable access for a wide variety of conditions.
About Matthew B. Harms, MD
Dr. Harms' post-doctoral and faculty work in neurogenetics led to the discovery of genes for dominant spinal muscular atrophy and limb-girdle muscular dystrophy type 1D. He sees patients in the Eleanor and Lou Gehrig ALS Center, the Adult Muscular Dystrophy Association Clinic, the Pediatric Muscular Dystrophy Association Clinic, and until recently, the ALS Clinic of the Bronx VA Hospital. His laboratory straddles Columbia's Motor Neuron Center and the Institute for Genomic Medicine, with a focus on generating, integrating, and analyzing clinical, genomic and transcriptomic datasets for amyotrophic lateral sclerosis and other neurological disorders.
About John W. Day, MD, PhD
Dr. Day has combined his expertise in synaptic physiology, genetics and neuromuscular medicine to help define the molecular mechanisms underlying myotonic dystrophy and other muscular dystrophies, neuropathies and ataxias. Under his leadership, the Stanford Neuromuscular Program is dedicated to the elucidation and treatment of neuromuscular diseases, integrating clinical care and clinical research with Stanford's basic science and translational programs. All Stanford pediatric and adult neuromuscular patients are asked to participate in research and are followed over time with functional evaluations. The Stanford Neuromuscular Program mission aligns fully with the goals of the MDA: to diagnose, investigate and characterize neuromuscular disorders precisely and completely; to develop novel treatments for neuromuscular disease; to incorporate novel treatments into the comprehensive care of patients with neuromuscular disorders; to advocate and support patients and families affected by neuromuscular disease so they can live life as fully and independently as possible; and to train the next generation of experts in neuromuscular diagnosis, care and research.
MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS, and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than$1 billionsince our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to life-changing therapies across multiple neuromuscular diseases. MDA's MOVR is the first and only data hub that aggregates clinical, genetic, and patient-reported data for multiple neuromuscular diseases to improve health outcomes and accelerate drug development. MDA supports the largest network of multidisciplinary clinics providing best in class care at more than 150 of the nation's top medical institutions. Our Resource Center serves the community with one-on-one specialized support, and we offer educational conferences, events, and materials for families and healthcare providers. Each year thousands of children and young adults learn vital life skills and gain independence at summer camp and through recreational programs, at no cost to families. For more information visitmda.org.
SOURCE Muscular Dystrophy Association
Here is the original post:
- Largest-Ever Study of Prostate Cancer Genomics in Black Men IDs Potential Targets for Precision Therapies - UCSF News Services - July 12th, 2020
- Researchers Discover Genetic Variants Linked to Type 2 Diabetes - HealthITAnalytics.com - July 12th, 2020
- Summerville Medical celebrates 1 year anniversary of obstetric consolidation - Journalscene.com - July 12th, 2020
- Researchers at U of T use stem cells to grow functional blood vessel cells found in liver - News@UofT - July 12th, 2020
- The Wilderness of Rare Genetic Diseases and the Parents Navigating It - The New York Times - July 12th, 2020
- This Company Wants to Rewrite the Future of Genetic DiseaseWithout Crispr Gene Editing - WIRED - July 12th, 2020
- Could induced pluripotent stem cells be the breakthrough genetics has been waiting for? - The New Economy - July 12th, 2020
- An intriguingbut far from provenHIV cure in the 'So Paulo Patient' - Science Magazine - July 12th, 2020
- First Extensive Validation Study of Saphyr for Constitutional Genetic Disorders by European Consortium Shows 100% Concordance to Standard Cytogenetics... - July 12th, 2020
- MyoKardia: The Precision Cardiac Medicine Company with Diversity and Inclusion at its Heart - BioSpace - July 12th, 2020
- From pandemic to rare disease, medical innovation is the answer - EURACTIV - July 12th, 2020
- COVID-19 Now Research Focus Of Health Database That Has Several Wisconsin Partners - WUWM - July 12th, 2020
- If you have this blood type, studies show youre at higher risk for the coronavirus - San Francisco Chronicle - July 12th, 2020
- How Accurate Are the Coronavirus Diagnostic and Antibody Tests? - Healthline - July 12th, 2020
- NIH researchers reframe dog-to-human aging comparisons - National Institutes of Health - July 12th, 2020
- The Prostate Cancer Foundation Collaboration With Pan-Cancer Consortium Clarifies And Promotes Consistent Use Of Common Terms For Biomarker And... - July 12th, 2020
- Worldwide genome research could change the course of medical history - The Big Smoke Australia - July 12th, 2020
- Post-PCI Mortality Higher in Blacks vs Whites, Comorbidities Aside - Medscape - July 12th, 2020
- A COVID-19 vaccine may come soon. Will the blistering pace backfire? - Science News - July 12th, 2020
- In the hunt for ALS treatments, researchers find promise in silencing genes - BioPharma Dive - July 12th, 2020
- Gene therapy innovations: Sarepta and Codiak partner on exosomes - Pharmaceutical Technology - July 12th, 2020
- NIH Funds Research to Understand How Genomics of Diverse Populations Affect Clinical Care - AJMC.com Managed Markets Network - July 11th, 2020
- ACMG's Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019--Journal is Ranked 13th of 177 Journals in Genetics & Heredity -... - July 11th, 2020
- Parasitic worms use their keen senses to wriggle through their hosts - University of Wisconsin-Madison - July 11th, 2020
- BridgeBio Pharma's Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology's 45th... - July 11th, 2020
- Genetic testing and hitching a ride with the British; In The News for July 10 - Medicine Hat News - July 11th, 2020
- A WHO-led mission may investigate the pandemic's origin. Here are the key questions to ask - Science Magazine - July 11th, 2020
- Scientists need to track genetic diversity of COVID-19 for effective vaccine: U of M study - CTV News Winnipeg - July 11th, 2020
- Global wildlife surveillance could provide early warning for next pandemic - Washington University School of Medicine in St. Louis - July 10th, 2020
- Bennett named chief of breast imaging section - Washington University School of Medicine in St. Louis - July 10th, 2020
- Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External Innovation - Business Wire - July 10th, 2020
- Search for cure for common parasitic infection focus of $5.5 million NIH grant - Washington University School of Medicine in St. Louis - July 10th, 2020
- Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company's Proprietary Approach to Addressing... - July 10th, 2020
- Trending: CRISPR And CRISPR-Associated Genes Market Research Key Players, Industry Overview and forecasts to | Thermo Fisher Scientific, Editas... - July 10th, 2020
- Europe Genetic Testing Services Market is expected to reach US$ 5840.9 Million by 2027 with CAGR of 11.4%. - Owned - July 10th, 2020
- Supreme Court to rule on constitutionality of genetic discrimination law - Medicine Hat News - July 10th, 2020
- Genetic fingerprints of first COVID19 cases help manage pandemic - News - The University of Sydney - July 10th, 2020
- Drug for Inherited ALS Shows Promise in Early-stage Trial - Technology Networks - July 10th, 2020
- Myriad Announces Partnership with OptraHEALTH to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients - BioSpace - July 6th, 2020
- Children's National Medical Center and AWS partner for genome project targeting COVID-19 - SiliconANGLE - July 6th, 2020
- Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer - BioSpace - July 6th, 2020
- Movers & Shakers, July 3 | BioSpace - BioSpace - July 6th, 2020
- The Future of Medicine Is Bespoke - Fair Observer - July 6th, 2020
- July: Genome sequencing rare diseases | News and features - University of Bristol - July 6th, 2020
- Dropping Race-Based eGFR Adjustment Gains Traction in US - Medscape - July 6th, 2020
- A New Generation of Coronavirus Tests Is Coming. Here's What to Expect. - The New York Times - July 6th, 2020
- Male fruit flies' decline in fertility with age is not only driven by changes in sperm - Mirage News - July 6th, 2020
- In the Future, Lab Mice Will Live in Computer Chips, Not Cages - Medscape - July 6th, 2020
- For cancer treatment and more, genetic-based precision medicine holds a lot of promise - Connecticut Magazine - May 31st, 2020
- Drug factories: GMOs and gene editing are poised to transform medicine. Here's how. - Genetic Literacy Project - May 31st, 2020
- How to know your risk factors for hypertension and whether high blood pressure is genetic - Insider - INSIDER - May 31st, 2020
- Venture capital found its footing in biotech. Then came the virus. - BioPharma Dive - May 31st, 2020
- Israeli Lab: Drugs For Gaucher Disease May Work Against Coronavirus, Other Viral Infections | Health News - NoCamels - Israeli Innovation News - May 31st, 2020
- Rapid Growth on Genetic Testing Market with COVID-19 Impact Analysis, Top Key Companies like Abbott Laboratories Bio-Rad Laboratories Inc.,... - May 31st, 2020
- insideHPC Special Report: HPC and AI for the Era of Genomics - insideHPC - May 31st, 2020
- More insight into the cytokine storm caused by Covid-19 could lead to a treatment - Health24 - May 31st, 2020
- UCalgary researchers launch 360-degree study of children and COVID-19 - UCalgary News - May 31st, 2020
- 4000 Years of contact, conflict and cultural change had little genetic impact in Near East - University of Birmingham - May 31st, 2020
- Precision Medicine Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty - May 31st, 2020
- NOT REAL NEWS: A look at what didn't happen this week - wausaupilotandreview.com - May 31st, 2020
- Precision Medicine Informs Cost-Effective Heart Disease Treatments - HealthITAnalytics.com - May 19th, 2020
- Colonizing Mars may require humanity to tweak its DNA - Space.com - May 19th, 2020
- Complement genes add to sex-based vulnerability in lupus and schizophrenia - Newswise - May 19th, 2020
- 23andMe Is Trying to Crack the Genetic Code Behind the Coronavirus - Motley Fool - May 19th, 2020
- Global Molecular Diagnostics Industry 2019-2029: Genetic Disorders, Cardiovascular Disorders, Infections and Cancer - Yahoo Finance UK - May 19th, 2020
- Prominent Cancer Researcher to Join DRI and Renown Health - GlobeNewswire - May 19th, 2020
- Research Roundup: HIV vaccination, diabetes two-in-one injection, hybrid fish genetics - The Stanford Daily - May 19th, 2020
- Singapore researches discover specific gene linked to Asian Lung Cancer - BSA bureau - May 19th, 2020
- Grant will help scientists break new ground in gene editing - Newswise - May 19th, 2020
- Genomic Medicine Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Ingersoll Rand, Johnson Controls, Daikin, United... - May 19th, 2020
- Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic... - May 19th, 2020
- Coronavirus immunity passports could create a world of 'us and them'. But here's why they make sense - Genetic Literacy Project - May 19th, 2020
- New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair - SciTechDaily - May 19th, 2020
- Scientists race to find a cure or vaccine for the coronavirus. Here are the top drugs in development - CNBC - May 19th, 2020
- WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? - Byline Times - May 19th, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market Size, Share, Trends and Forecast 2026 by Major Players and Business Opportunities Caribou... - May 19th, 2020
- Researchers: Disease affecting kids could be in the genes - Newsday - May 19th, 2020
- From Competition To Sharing: How Her Childrens Rare Disease Led Sharon Terry To Revolutionize Medical Research - Forbes - May 9th, 2020
- Infection rates may have links to cancer - Medical News Today - May 9th, 2020
- Twin peeks: Stanford inherits twin registry, expanding research options - Stanford Medical Center Report - May 9th, 2020